ClinicalTrials.gg
Status unknownNCT04126538Updated Mar 29, 2022

Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics

A Phase 1 interventional study of pirfenidone capsule and pirfenidone capsule in Renal Insufficiency, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-29.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Renal Insufficiency with a site in China — 16 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · China.

Planned enrollment
34th of 48
24 · median 41
Started
2019
with 4 others
Phase 1
22 of 61
4 open now
Registered
20th of 61
by date

Among the 61 studies in Renal Insufficiency with a site in China, this one is the 34th largest by planned enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2019, is one of 22 in phase 1, and was the 20th registered.

Renal Insufficiency

1,412 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

16 of the 61 studies in Renal Insufficiency with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Renal Insufficiency with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and pharmacokinetic characteristics of pirfenidone capsules in chronic kidney disease G2 and G3a patients, and to provide a basis for the phase II clinical trial program

03

Conditions studied

  • Renal Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients with chronic kidney disease, both male and female(Patient group);
  2. 18-70 years old, including 18 years old and 70 years old(Patient group);
  3. weight: male ≥50kg, female ≥45kg, 18≤≤26 (BMI= weight (kg)/height 2 (m2))(Patient group);
  4. the stage of chronic kidney disease was G2 or G3a, indicating mild or moderate decrease in , i.e., glomerular filtration rate was 45≤eGFR(ml/min/1.73m2) ≤89 (calculated according to ckd-epi formula)(Patient group);
  5. from 24h before the start of the study to the end of the study, subjects who agree to abstain from tobacco, alcohol, fruit juice, caffeine and tea(Patient group);
  6. I have had a detailed understanding of the nature, significance, possible benefits, possible inconvenience and potential risks of the trial before the study, and I have volunteered to participate in the clinical trial. I am able to communicate well with the investigator, comply with the requirements of the whole study, and have the ability to understand and sign the written .(Patient group);
  7. gender: Chinese healthy subjects, male and female(Control group);
  8. 18-70 years old, including 18 years old and 70 years old(Control group);
  9. weight: male ≥50kg, female ≥45kg, 18≤BMI≤26 (BMI= weight (kg)/height 2 (m2))(Control group);
  10. from 24h before the start of the study to the end of the study, subjects who agree to abstain from tobacco, alcohol, fruit juice, caffeine and tea(Control group);
  11. those who have detailed understanding of the nature, significance, potential benefits, possible inconveniences and potential risks of the trial before the study, who have volunteered to participate in the clinical trial, who can communicate well with the investigator, comply with the requirements of the whole study, and who are able to understand and sign a written informed consent(Control group);

Exclusion criteria

Exclusion Criteria:

  1. (Physician visits) have participated in any other clinical trials within the first three months of the trial(Patient group);
  2. (preliminary) of any process may affect test security, or drug in the body of the disease, not including chronic kidney disease (CKD), including but not limited to: heart, liver, gastrointestinal tract, immune system and respiratory system always or the existing system diseases (especially for any impact on drug absorption of gastrointestinal diseases (such as irritable bowel syndrome symptoms, bowel disease or inflammatory bowel disease), active pathological bleeding (such as peptic ulcer), urticaria, eczema, dermatitis, epilepsy, allergic rhinitis, asthma, etc.)(Patient group);
  3. (consultation) allergy: if there are two or more drugs, food allergy history (including experimental drugs), lactose intolerance(Patient group);
  4. (consultation) any drugs that inhibit or induce drug metabolism in the liver (common liver enzyme inducers: barbiturates, carbamazepine, aminoximate, griseofulvin, aminopropyl, phenytoin, gromitol, rifampin, dexamethasone; Common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamide)(Patient group);
  5. (consultation) failure to follow a uniform diet (such as intolerance to standard meals, etc.) or difficulty swallowing(Patient group);
  6. (consultation) unable to tolerate venipuncture and/or having a history of blood or acupuncture(Patient group);
  7. (consultation) patients who have been drinking excessive amounts of tea, coffee or caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.) within 24 hours before the first administration of the drug(Patient group);
  8. (consultation) previous binge drinking (i.e., male drinking more than 28 units per week and female drinking more than 21 units per week (1 unit contains 14g alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had regularly consumed alcohol (more than 14 units per week) during the 6 months prior to the trial; Or who had taken any alcoholic product within 24 hours of initial administration(Patient group);
  9. (consultation) those who had donated blood or suffered massive bleeding (greater than 450 mL) within 3 months before the first administration of the study, or who planned to donate blood or blood components during the study period or within 3 months after the end of the study(Patient group);
  10. (consultation) acute disease during the screening phase before study or before study medication(Patient group);
  11. (consultation) patients who had taken food or drinks containing enzymes that can induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice, orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before the first administration were studied(Patient group);
  12. pregnant or lactating women, and subjects (or their partners) who have a pregnancy plan during the trial and within 3 months after the end of the study and who do not agree to use non-drug during the trial(Patient group);
  13. (consultation) those who have had surgery within three months before the screening period, or who are planning to have surgery during the study period, and those who have had surgery that will affect drug absorption, distribution, metabolism and excretion(Patient group);
  14. (consultation) previous history of drug abuse or drug abuse(Patient group);
  15. (consultation) persons who have smoked more than 5 cigarettes per day in the 14 days before screening, or who cannot stop using any tobacco products during the trial(Patient group);
  16. screening for smoking or using any tobacco products up to admission(Patient group);
  17. screening phase physical examination, vital signs measurement, examination, laboratory examination (hematuria routine, blood coagulation function, blood pregnancy (women of childbearing age only)) and investigator determination of abnormalities (excluding abnormalities caused by chronic kidney disease). Abnormal liver function examination (, AST, ALP, gamma GT, TP, Alb, A/G, t-bil, d-bil) suggested liver disease or liver injury. Renal function test SCr > 400 mol/L; Abnormal blood electrolyte examination (K+, Na+, Cl-, Ca2+) suggested high potassium or acidosis.(Patient group)
  18. nicotine positive test(Patient group);
  19. alcohol breath test with test results greater than 0.0mg/100ml(Patient group);
  20. positive urine drug screening(Patient group);
  21. surface antigen positive, or antibody positive, or syphilis spirochete antibody positive, or antibody positive(Patient group);
  22. the investigator considers that there are any circumstances that may affect the subject's or adherence to the study protocol, or participation in the study may affect the study results or their own safety.(Patient group);
  23. (Physician visits)those who participated in any other clinical trials three months prior to the trial(Control group);
  24. (preliminary) of any process may affect test security, or drug in the body of the disease, including but not limited to: heart, liver, kidney, endocrine, the digestive tract, immune system and respiratory system always or the existing system diseases (especially cardiovascular diseases including cardiovascular disease risk, any impact on drug absorption of gastrointestinal diseases (such as irritable bowel syndrome symptoms, bowel disease or inflammatory bowel disease), active pathological bleeding (such as peptic ulcer), urticaria, eczema, dermatitis, epilepsy, allergic rhinitis, asthma, etc.)(Control group);
  25. (consultation) allergy: if there are two or more drugs, food allergy history (including experimental drugs), lactose intolerance(Control group);
  26. (consultation) any drugs that inhibit or induce drug metabolism in the liver (common liver enzyme inducers: barbiturates, carbamazepine, aminoximate, griseofulvin, aminopropyl, phenytoin, gromitol, rifampin, dexamethasone; Common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamide); Or have used any medicines (including Chinese herbal medicines) or health supplements within 14 days prior to initial administration(Control group);
  27. (consultation) failure to follow a uniform diet (such as intolerance to standard meals, etc.) or difficulty swallowing(Control group);
  28. (consultation) unable to tolerate venipuncture and/or having a history of blood or acupuncture(Control group);
  29. (consultation) patients who have been drinking excessive amounts of tea, coffee or caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.) within 24 hours before the first administration of the drug(Control group);
  30. (consultation) previous binge drinking (i.e., male drinking more than 28 units per week and female drinking more than 21 units per week (1 unit contains 14g alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had regularly consumed alcohol (more than 14 units per week) during the 6 months prior to the trial; Or who had taken any alcoholic product within 24 hours of initial administration(Control group);
  31. (consultation) those who had donated blood or suffered massive bleeding (greater than 450 mL) within 3 months before the first administration of the study, or who planned to donate blood or blood components during the study period or within 3 months after the end of the study(Control group);
  32. (consultation) acute disease during the screening phase before study or before study medication(Control group);
  33. (consultation) patients who had taken food or drinks containing enzymes that can induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice, orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before the first administration were studied(Control group);
  34. pregnant or lactating women, and subjects (or their partners) who have a pregnancy plan during the trial and within 3 months after the end of the study and who do not agree to use non-drug contraception during the trial(Control group);
  35. (consultation) those who have had surgery within three months before the screening period, or who are planning to have surgery during the study period, and those who have had surgery that will affect drug absorption, distribution, metabolism and excretion(Control group);
  36. (consultation) previous history of drug abuse or drug abuse(Control group);
  37. (consultation) persons who have smoked more than 5 cigarettes per day in the 14 days before screening, or who cannot stop using any tobacco products during the trial(Control group);
  38. screening for smoking or using any tobacco products up to admission(Control group);
  39. screening phase physical examination, vital signs measurement, electrocardiogram examination, b-mode ultrasound examination, laboratory examination [blood routine, urine routine, blood biochemistry, blood coagulation function, blood pregnancy (women of childbearing age only)], and the investigator judged that abnormalities were clinically significant(Control group);
  40. those with positive nicotine test results(Control group);
  41. alcohol breath test with test results greater than 0.0mg/100ml(Control group);
  42. positive urine drug screening(Control group);
  43. hepatitis b surface antigen positive, or hepatitis c antibody positive, or syphilis spirochete antibody positive, or HIV antibody positive(Control group);
  44. the investigator considers that there are any circumstances that may affect the subject's informed consent or adherence to the study protocol, or participation in the study may affect the study results or their own safety.(Control group).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Patient group

    Patients with chronic kidney disease take pirfenidone capsule 400mg once orally

    Drug: pirfenidone capsule

  • Experimental
    Control group

    Healthy subjects take pirfenidone capsule 400mg once orally

    Drug: pirfenidone capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma drug concentrations of pirfenidone

    Time frame: up to 24 weeks

  2. Urine concentration of pirfenidone

    Time frame: up to 24 weeks

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: up to 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Wuhan Union Hospital
    Wuhan, Hubei 430022, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Nov 2021, 26 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 26 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2019
First posted
Oct 15, 2019
StartActual
Aug 27, 2019
Primary completionActual
Nov 25, 2021
CompletionEst.
Jun 30, 2022
Last update
Mar 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04126538
Responsible party
Sponsor
First posted
Oct 15, 2019
Start date
Aug 27, 2019
Primary completion
Nov 25, 2021
Completion
Jun 30, 2022 (estimated)
Last update
Mar 29, 2022

Study contacts

Shaojun Shi, Doctor
Contact
sjshicn@163.com
027-85726085
Shaojun Shaojun, Doctor
principal investigator · Wuhan Union Hospital, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion